Eli Lilly and Company (NYSE:LLY) Stock Jumps 3.7% – Should You Buy?

Posted by George Bondi on Oct 15th, 2026

Eli Lilly and Company logo Eli Lilly and Company (NYSE:LLY – Get Free Report) traded up 3.7% during trading on Thursday. The company traded as high as $1,275.88 and last traded at $1,253.9370. Approximately 3,730,706 shares were traded during mid-day trading, an increase of 26% from the average session volume of 2,957,309 shares. The stock had previously closed at $1,208.74.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: New analyses support Omvoh (mirikizumab) as a potential higher-standard treatment for inflammatory bowel disease. In the LUCENT-2 ulcerative-colitis study, 27.7% of treated patients achieved comprehensive corticosteroid-free disease control, while 20.4% of Crohn’s disease patients in VIVID-1 achieved corticosteroid-free deep remission. Benefits were also observed among patients who had previously failed biologic therapy, strengthening Omvoh’s commercial positioning. Omvoh composite outcomes data
Positive Sentiment: Retatrutide, Lilly’s experimental triple-agonist obesity drug, remains a major future growth opportunity after reportedly producing substantial weight loss in late-stage testing. A potential regulatory filing in early 2027 gives investors another catalyst beyond Mounjaro and Zepbound, although approval is not guaranteed. Retatrutide availability
Positive Sentiment: Lilly is broadening its pipeline through oncology and immunology activity, including a collaboration evaluating Adlai Nortye’s investigational AN4035 with cetuximab, plus updates involving donanemab and lebrikizumab. These programs add longer-term diversification beyond obesity medicines. Adlai Nortye collaboration
Neutral Sentiment: Lilly will release third-quarter 2026 results on October 29. Investors will focus on demand for its GLP-1 products, supply expansion, margins and whether management maintains its full-year EPS outlook. Lilly third-quarter earnings date
Negative Sentiment: After a powerful multi-year rally and a market capitalization above $1 trillion, valuation and profit-taking could limit further upside. Commentary also raises the possibility of a stock split, but a split would not change Lilly’s underlying earnings or intrinsic value. Eli Lilly stock split analysis

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Cantor Fitzgerald lifted their price target on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the company an “overweight” rating in a report on Thursday, October 8th. JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an “overweight” rating in a report on Monday, September 28th. Berenberg Bank set a $1,400.00 price objective on shares of Eli Lilly and Company and gave the company a “buy” rating in a research report on Tuesday, September 15th. Sanford C. Bernstein lifted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research note on Tuesday, July 14th. Finally, Leerink Partners boosted their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,313.43.

View Our Latest Report on Eli Lilly and Company

Eli Lilly and Company Trading Up 3.7%

The company has a fifty day moving average of $1,177.42 and a two-hundred day moving average of $1,104.28. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The stock has a market capitalization of $1.18 trillion, a price-to-earnings ratio of 42.08, a price-to-earnings-growth ratio of 1.50 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter last year, the company posted $6.31 earnings per share. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts expect that Eli Lilly and Company will post 34.79 EPS for the current year.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Coastal Bridge Advisors LLC acquired a new position in Eli Lilly and Company during the second quarter valued at approximately $2,959,000. Mosaic Family Wealth Partners LLC increased its position in Eli Lilly and Company by 70.6% in the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock valued at $4,144,000 after buying an additional 1,430 shares in the last quarter. Moran Wealth Management LLC increased its position in Eli Lilly and Company by 85.6% in the 2nd quarter. Moran Wealth Management LLC now owns 20,903 shares of the company’s stock valued at $25,072,000 after buying an additional 9,638 shares in the last quarter. Generali Investments Management Co LLC raised its stake in Eli Lilly and Company by 17.5% during the 2nd quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company’s stock worth $12,258,000 after buying an additional 1,521 shares during the period. Finally, Amundi raised its stake in Eli Lilly and Company by 9.9% during the 1st quarter. Amundi now owns 5,055,025 shares of the company’s stock worth $4,649,464,000 after buying an additional 454,549 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.